Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8027255 | 0.90 | PSEN1 (0.33) | — | |
| SCHEMBL8021272 | 0.87 | HRH3 (0.33) | PRMT5WDR77 | |
| SCHEMBL8018731 | 0.87 | HDAC8 (0.37) | PRMT5WDR77 | |
| SCHEMBL8030735 | 0.86 | AKR1C3 (0.34) | — | |
| SCHEMBL8015181 | 0.86 | HRH3 (0.33) | — | |
| SCHEMBL8028979 | 0.85 | MAPT (0.37) | — | |
| SCHEMBL8028316 | 0.84 | AOC3 (0.37) | — | |
| SCHEMBL13786768 | 0.84 | MAP3K8 (0.39) | — | |
| SCHEMBL13786764 | 0.83 | NPC1 (0.34) | — | |
| SCHEMBL13786766 | 0.83 | JAK2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192154-A1 | SULTAM DERIVATIVES | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-30 | — | — | US | disclosed |
| WO-2009084501-A1 | SULTAM DERIVATIVE | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192154-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, ADAMTS1 | PRMT5 1666/4885WDR77 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.